Ricevi le ultime notizie sulle azioni Vanda Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di VNDA

Ultime notizie per

VANDA PHARMACEUTICALS INC

Vanda Pharma

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals Inc

Press Releases

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Earnings

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Penny Stocks

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

VNDA

Abeona Therapeutics

AC Immune

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Editas Medicine

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Foghorn Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Humacyte

Jade Biosciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

PepGen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Replimune Group

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Vor Biopharma

Zura Bio Limited - Class A Ordinary shares

Comments

Vanda Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO